ECSP14015609A - Inhibidores de pde9 con estructura básica de imidazotriazinona - Google Patents
Inhibidores de pde9 con estructura básica de imidazotriazinonaInfo
- Publication number
- ECSP14015609A ECSP14015609A ECIEPI201415609A ECPI201415609A ECSP14015609A EC SP14015609 A ECSP14015609 A EC SP14015609A EC IEPI201415609 A ECIEPI201415609 A EC IEPI201415609A EC PI201415609 A ECPI201415609 A EC PI201415609A EC SP14015609 A ECSP14015609 A EC SP14015609A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- formula
- effective amount
- imidazotriazinone
- basic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos, que son inhibidores de la enzima PDE9. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para preparar compuestos de fórmula (I). La presente invención proporciona además un método para tratar un sujeto que padece un trastorno neurodegenerativo que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I). La presente invención proporciona además un compuesto de fórmula (I) para su uso en un método para tratar un sujeto que padece un trastorno psiquiátrico que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012070718 | 2012-01-26 | ||
| CN2012080208 | 2012-08-16 | ||
| PCT/EP2013/051451 WO2013110768A1 (en) | 2012-01-26 | 2013-01-25 | Pde9 inhibitors with imidazo triazinone backbone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14015609A true ECSP14015609A (es) | 2015-12-31 |
Family
ID=47603775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201415609A ECSP14015609A (es) | 2012-01-26 | 2014-08-25 | Inhibidores de pde9 con estructura básica de imidazotriazinona |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9434733B2 (es) |
| EP (2) | EP3178820B1 (es) |
| CN (2) | CN104093720B (es) |
| AP (1) | AP2014007820A0 (es) |
| AU (2) | AU2013213603B2 (es) |
| BR (1) | BR112014018199A8 (es) |
| CO (1) | CO7020913A2 (es) |
| CR (1) | CR20140361A (es) |
| DO (1) | DOP2014000175A (es) |
| EC (1) | ECSP14015609A (es) |
| HK (1) | HK1199879A1 (es) |
| MX (1) | MX351582B (es) |
| PH (1) | PH12014501695B1 (es) |
| SG (1) | SG11201403909RA (es) |
| WO (1) | WO2013110768A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2619208B1 (en) | 2010-09-20 | 2016-11-09 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| EP4640259A3 (en) | 2010-10-08 | 2025-11-12 | Fisher & Paykel Healthcare Limited | Mask seal assembly |
| BR112015007731B1 (pt) | 2011-10-10 | 2022-05-31 | H. Lundbeck A/S | Composto, composição farmacêutica que o compreende e uso do mesmo |
| BR112014018199A8 (pt) | 2012-01-26 | 2021-03-02 | H Lundbeck As | inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação |
| HK1206726A1 (en) | 2012-03-19 | 2016-01-15 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| MX2018016127A (es) * | 2016-07-06 | 2019-05-30 | Imara Inc | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. |
| WO2018073251A1 (en) | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| EP3541784B1 (en) * | 2016-11-18 | 2023-09-13 | Integrative Research Laboratories Sweden AB | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| JP7053645B2 (ja) * | 2017-02-23 | 2022-04-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 化合物ｉｉｉの新しい医学的使用 |
| CN115746003B (zh) * | 2017-05-26 | 2024-08-09 | 卡都瑞恩医药公司 | 制备和使用pde9抑制剂的方法 |
| CN110003213B (zh) * | 2018-01-04 | 2021-10-08 | 南京农业大学 | 苯并咪唑并三嗪酮类化合物、制备方法及应用 |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| CA3110680A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| EP3965768A1 (en) * | 2019-05-07 | 2022-03-16 | Imara Inc. | Pde9 inhibitors for treating thalassemia |
| CN113072556B (zh) * | 2021-03-30 | 2022-02-01 | 牡丹江医学院 | 一种用于治疗胶质瘤的药物及其制备方法 |
| CN120897742A (zh) * | 2022-11-15 | 2025-11-04 | 福睿德姆生物科学公司 | 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2395558C (en) | 1997-11-12 | 2007-07-17 | Bayer Aktiengesellschaft | Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| IL144156A0 (en) | 1999-01-20 | 2002-05-23 | Dresden Arzneimittel | Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments |
| JP2005508978A (ja) | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療 |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
| US6684626B1 (en) | 2002-07-30 | 2004-02-03 | General Electric Company | Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2005041972A1 (en) | 2003-10-31 | 2005-05-12 | Pfizer Products Inc. | Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US8299080B2 (en) | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
| RS52166B (sr) * | 2007-05-11 | 2012-08-31 | Pfizer Inc. | Amino-heterociklična jedinjenja |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| KR20100117059A (ko) | 2007-12-10 | 2010-11-02 | 글락소 그룹 리미티드 | 멜라닌-농축 호르몬 수용체 1 길항제로서의 비스-피리딜피리돈 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2011011712A1 (en) | 2009-07-24 | 2011-01-27 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
| WO2011028820A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| EP2619208B1 (en) | 2010-09-20 | 2016-11-09 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| BR112014018199A8 (pt) | 2012-01-26 | 2021-03-02 | H Lundbeck As | inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação |
-
2013
- 2013-01-25 BR BR112014018199A patent/BR112014018199A8/pt active Search and Examination
- 2013-01-25 US US14/374,278 patent/US9434733B2/en active Active
- 2013-01-25 CN CN201380006255.2A patent/CN104093720B/zh active Active
- 2013-01-25 MX MX2014008912A patent/MX351582B/es active IP Right Grant
- 2013-01-25 EP EP17152165.1A patent/EP3178820B1/en active Active
- 2013-01-25 CN CN201710176546.6A patent/CN107082783B/zh active Active
- 2013-01-25 WO PCT/EP2013/051451 patent/WO2013110768A1/en not_active Ceased
- 2013-01-25 HK HK15100346.4A patent/HK1199879A1/xx unknown
- 2013-01-25 AU AU2013213603A patent/AU2013213603B2/en active Active
- 2013-01-25 EP EP13701270.4A patent/EP2807163B1/en active Active
- 2013-01-25 AP AP2014007820A patent/AP2014007820A0/xx unknown
- 2013-01-25 SG SG11201403909RA patent/SG11201403909RA/en unknown
-
2014
- 2014-07-24 CO CO14161415A patent/CO7020913A2/es unknown
- 2014-07-24 CR CR20140361A patent/CR20140361A/es unknown
- 2014-07-25 DO DO2014000175A patent/DOP2014000175A/es unknown
- 2014-07-25 PH PH12014501695A patent/PH12014501695B1/en unknown
- 2014-08-25 EC ECIEPI201415609A patent/ECSP14015609A/es unknown
-
2016
- 2016-04-04 US US15/089,819 patent/US9533992B2/en active Active
- 2016-11-22 US US15/358,168 patent/US9850249B2/en active Active - Reinstated
-
2017
- 2017-02-09 AU AU2017200886A patent/AU2017200886B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2014000175A (es) | 2014-08-31 |
| WO2013110768A1 (en) | 2013-08-01 |
| MX2014008912A (es) | 2014-08-26 |
| US9434733B2 (en) | 2016-09-06 |
| CN104093720A (zh) | 2014-10-08 |
| EP3178820B1 (en) | 2017-12-20 |
| PH12014501695B1 (en) | 2019-06-03 |
| EP2807163A1 (en) | 2014-12-03 |
| CN107082783B (zh) | 2019-03-22 |
| US20170081333A1 (en) | 2017-03-23 |
| AU2013213603A1 (en) | 2014-07-24 |
| US9533992B2 (en) | 2017-01-03 |
| US9850249B2 (en) | 2017-12-26 |
| CN107082783A (zh) | 2017-08-22 |
| AP2014007820A0 (en) | 2014-07-31 |
| PH12014501695A1 (en) | 2014-10-20 |
| AU2017200886B2 (en) | 2018-01-18 |
| EP3178820A1 (en) | 2017-06-14 |
| AU2013213603B2 (en) | 2017-02-02 |
| CO7020913A2 (es) | 2014-08-11 |
| US20150045348A1 (en) | 2015-02-12 |
| MX351582B (es) | 2017-10-20 |
| BR112014018199A8 (pt) | 2021-03-02 |
| US20160213674A1 (en) | 2016-07-28 |
| EP2807163B1 (en) | 2017-03-22 |
| AU2017200886A1 (en) | 2017-03-02 |
| CN104093720B (zh) | 2017-04-12 |
| CR20140361A (es) | 2014-11-11 |
| SG11201403909RA (en) | 2014-10-30 |
| HK1199879A1 (en) | 2015-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14015609A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| IN2015DN02829A (es) | ||
| ECSP13012698A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| CR20120319A (es) | Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a | |
| CO6321263A2 (es) | Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| DOP2012000168A (es) | Derivados de 2-arimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| MX2012006715A (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a. | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
| DOP2013000108A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a |